Cargando…

A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis

Background: Pneumococcal pneumonia is an important cause of morbidity and mortality amongst patients with inflammatory arthritis. Vaccination is recommended by the National Institute for Health and Care Excellence (NICE) but it remains unclear how vaccine efficacy is impacted by different immunosupp...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagra, Deepak, Bechman, Katie, Adas, Maryam, Yang, Zijing, Alveyn, Edward, Subesinghe, Sujith, Rutherford, Andrew, Allen, Victoria, Patel, Samir, Russell, Mark D., Cope, Andrew, Norton, Sam, Galloway, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674424/
https://www.ncbi.nlm.nih.gov/pubmed/38006012
http://dx.doi.org/10.3390/vaccines11111680
_version_ 1785140824723423232
author Nagra, Deepak
Bechman, Katie
Adas, Maryam
Yang, Zijing
Alveyn, Edward
Subesinghe, Sujith
Rutherford, Andrew
Allen, Victoria
Patel, Samir
Russell, Mark D.
Cope, Andrew
Norton, Sam
Galloway, James
author_facet Nagra, Deepak
Bechman, Katie
Adas, Maryam
Yang, Zijing
Alveyn, Edward
Subesinghe, Sujith
Rutherford, Andrew
Allen, Victoria
Patel, Samir
Russell, Mark D.
Cope, Andrew
Norton, Sam
Galloway, James
author_sort Nagra, Deepak
collection PubMed
description Background: Pneumococcal pneumonia is an important cause of morbidity and mortality amongst patients with inflammatory arthritis. Vaccination is recommended by the National Institute for Health and Care Excellence (NICE) but it remains unclear how vaccine efficacy is impacted by different immunosuppressive agents. Our objective was to compare the chance of a seroconversion following vaccination against pneumococcus in patients with inflammatory arthritis to that in the general population, as well as to compare the chance of seroconversion across different targeted therapies. Methods: We searched MEDLINE, Embase and the Cochrane Library databases from inception until 20 June 2023. We included randomized controlled trials and observational studies. Aggregate data were used to undertake a pairwise meta-analysis. Our primary outcome of interest was vaccine seroconversion. We accepted the definition of serological response reported by the authors of each study. Results: Twenty studies were identified in the systematic review (2807 patients) with ten reporting sufficient data to be included in the meta-analysis (1443 patients). The chance of seroconversion in patients receiving targeted therapies, relative to the general population, was 0.61 (95% CI 0.35 to 1.08). The reduced odds of response were skewed strongly by the effects of abatacept and rituximab with no difference between patients on TNF inhibitors (TNFis) or IL-6 inhibition and healthy controls. Within different inflammatory arthritis populations the findings remained consistent, with rituximab having the strongest negative impact on vaccine response. TNF inhibition monotherapy was associated with a greater chance of vaccine response compared with methotrexate (2.25 (95% CI 1.28 to 3.96)). JAK inhibitor (JAKi) studies were few in number and did not present comparable vaccine response endpoints to include in the meta-analysis. The information available does not suggest any significant detrimental effects of JAKi on vaccine response. Conclusion: This updated meta-analysis confirms that, for most patients with inflammatory arthritis, pneumococcal vaccine can be administered with confidence and that it will achieve comparable seroconversion rates to the healthy population. Patients on rituximab were the group least likely to achieve a response and further research is needed to explore the value of multiple-course pneumococcal vaccination schedules in this population.
format Online
Article
Text
id pubmed-10674424
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106744242023-11-02 A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis Nagra, Deepak Bechman, Katie Adas, Maryam Yang, Zijing Alveyn, Edward Subesinghe, Sujith Rutherford, Andrew Allen, Victoria Patel, Samir Russell, Mark D. Cope, Andrew Norton, Sam Galloway, James Vaccines (Basel) Systematic Review Background: Pneumococcal pneumonia is an important cause of morbidity and mortality amongst patients with inflammatory arthritis. Vaccination is recommended by the National Institute for Health and Care Excellence (NICE) but it remains unclear how vaccine efficacy is impacted by different immunosuppressive agents. Our objective was to compare the chance of a seroconversion following vaccination against pneumococcus in patients with inflammatory arthritis to that in the general population, as well as to compare the chance of seroconversion across different targeted therapies. Methods: We searched MEDLINE, Embase and the Cochrane Library databases from inception until 20 June 2023. We included randomized controlled trials and observational studies. Aggregate data were used to undertake a pairwise meta-analysis. Our primary outcome of interest was vaccine seroconversion. We accepted the definition of serological response reported by the authors of each study. Results: Twenty studies were identified in the systematic review (2807 patients) with ten reporting sufficient data to be included in the meta-analysis (1443 patients). The chance of seroconversion in patients receiving targeted therapies, relative to the general population, was 0.61 (95% CI 0.35 to 1.08). The reduced odds of response were skewed strongly by the effects of abatacept and rituximab with no difference between patients on TNF inhibitors (TNFis) or IL-6 inhibition and healthy controls. Within different inflammatory arthritis populations the findings remained consistent, with rituximab having the strongest negative impact on vaccine response. TNF inhibition monotherapy was associated with a greater chance of vaccine response compared with methotrexate (2.25 (95% CI 1.28 to 3.96)). JAK inhibitor (JAKi) studies were few in number and did not present comparable vaccine response endpoints to include in the meta-analysis. The information available does not suggest any significant detrimental effects of JAKi on vaccine response. Conclusion: This updated meta-analysis confirms that, for most patients with inflammatory arthritis, pneumococcal vaccine can be administered with confidence and that it will achieve comparable seroconversion rates to the healthy population. Patients on rituximab were the group least likely to achieve a response and further research is needed to explore the value of multiple-course pneumococcal vaccination schedules in this population. MDPI 2023-11-02 /pmc/articles/PMC10674424/ /pubmed/38006012 http://dx.doi.org/10.3390/vaccines11111680 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Nagra, Deepak
Bechman, Katie
Adas, Maryam
Yang, Zijing
Alveyn, Edward
Subesinghe, Sujith
Rutherford, Andrew
Allen, Victoria
Patel, Samir
Russell, Mark D.
Cope, Andrew
Norton, Sam
Galloway, James
A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
title A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
title_full A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
title_fullStr A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
title_full_unstemmed A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
title_short A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
title_sort systematic review and meta-analysis of anti-rheumatic drugs and pneumococcal vaccine immunogenicity in inflammatory arthritis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674424/
https://www.ncbi.nlm.nih.gov/pubmed/38006012
http://dx.doi.org/10.3390/vaccines11111680
work_keys_str_mv AT nagradeepak asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT bechmankatie asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT adasmaryam asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT yangzijing asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT alveynedward asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT subesinghesujith asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT rutherfordandrew asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT allenvictoria asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT patelsamir asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT russellmarkd asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT copeandrew asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT nortonsam asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT gallowayjames asystematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT nagradeepak systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT bechmankatie systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT adasmaryam systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT yangzijing systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT alveynedward systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT subesinghesujith systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT rutherfordandrew systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT allenvictoria systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT patelsamir systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT russellmarkd systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT copeandrew systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT nortonsam systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis
AT gallowayjames systematicreviewandmetaanalysisofantirheumaticdrugsandpneumococcalvaccineimmunogenicityininflammatoryarthritis